SUMMARY OF RISK MANAGEMENT PLAN FOR OLEPTISS (DEFERASIROX) - VERSION 20.1

This is a summary of the RMP for Oleptiss. The RMP details important risks of Oleptiss, how these risks can be minimized, and how more information will be obtained about Oleptiss's risks and uncertainties (missing information).

Oleptiss's SmPC and its package leaflet give essential information to healthcare professionals and patients on how Oleptiss should be used.

Important new concerns or changes to the current ones will be included in updates of Oleptiss's RMP.

I. The medicine and what it is used for

Oleptiss is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients with thalassemia, Sickle Cell Disease (SCD), Myelodysplasia Syndrome (MDS) or other rare anemias, and for the treatment of chronic iron overload in patients with Non-transfusion-dependent thalassaemias (NTDT) syndromes.

II. Risks associated with the medicine and activities to minimize or further characterize the risks.

Important risks of Oleptiss, together with measures to minimize such risks and the proposedstudies for learning more about Oleptiss's risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly.
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In addition to these measures, information about adverse reactions is collected continuously andregularly analyzed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Oleptiss are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Oleptiss.

SUMMARY OF RISK MANAGEMENT PLAN FOR OLEPTISS (DEFERASIROX) - VERSION 20.1

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing Information	
Important identified risks	• Renal disorders (increased serum creatinine, acute renal failure, renal tubular disorders ([acquired Fanconi's syndrome]) • Increased liver transaminases / Hepatic failure • Gastrointestinal hemorrhage and ulcers; esophagitis • Hearing loss • Lens opacities, retinal changes and optic neuritis
Important potential risks	• Compliance with posology and biological monitoring • Medication errors due to switching between Exjade FCT/granules and generic versions of Oleptiss DT
Missing information	• Long term safety in pediatric NTDT patients aged 10 to 17 years • Safety of new formulation (FCT)

II.B Summary of important risks

Important identified: Renal disorders (increased serum creatinine, acute renal failure, renal tubular disorders [acquired Fanconi's syndrome])	
Evidence for linking the risk to the medicine	In thalassemia patients 0.5% of patients are reported to develop renal tubular dysfunction and 3.1% of patients progressed to dialysis therapy and 8% had a reduced CrCl. Renal tubular abnormalities, including increased urinary excretion of proteins and of tubular enzymes, have been reported in 30% of 250 patients with β-thalassemia. Progressive renal insufficiency, generally heralded by the appearance of increasing proteinuria, hypertension and hematuria occurs in 5-18% of

	patientswith SCD and can require hemodialysis or renal transplantation and contributes to 18% of deaths in patients older than 40 years. Acute renal failure has been described as part of a multi-organ failure syndrome that accompanies pain crises in SCD patients and is present in 10% of patients hospitalized with SCD. Renal failure contributes to 18% of deaths in SCD patients older than 40 years. In SCD, 26% of 381 patients were reported to have proteinuria, 13% at or closeto the nephritic range. It was reported that 2.3% of MDS patients have renal disorders. Myelodysplastic syndrome patients are generally elderly and have serum creatinine levels that are close to or slightly > ULN due to the normal aging process.
Risk factors and risk groups	Analyses showed that patients receiving high doses of Oleptiss DT (20 or 30 mg/kg) and a low iron intake from infrequent blood transfusions were more likely to develop creatinine increases. Elderly patients were more likely to develop creatinine values > ULN though, as explained above, the magnitude ofincrease in comparison to baseline was no higher in these patients. Patients with pre-existing renal conditions or patients who are receiving medicinal products that depress renal function may be at higher risk of complications including ARF. In clinical studies a relationship between iron status (liver iron and ferritin concentrations), the rate of iron removal and renal effects has been observed. As with other iron chelator treatment, the risk of toxicity may be increased when inappropriately high doses of Oleptiss are given in patients with a low iron burden or with serum ferritin levels that are only slightly elevated.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.2 Posologyand method of administration 4.3 Contraindications, and 4.4 Special warnings and precautions for use. Relevant terms are included as ADRs Section 4.8 Undesirable effects. **Additional risk minimization measures** None

SUMMARY OF RISK MANAGEMENT PLAN FOR OLEPTISS (DEFERASIROX) - VERSION 20.1

Important identified risk: Increased liver transaminases / Hepatic failure	
Evidence for linking the risk to the medicine	**Increased liver transaminases** Elevated liver transaminases have been correlated with increased LIC in patients with β-thalassemia. Studies have shown that hepatomegaly is seen in 50% of patients with SCD, hepatitis in 11% of patients, and approximately one third of SCD patients will have a form of hepatic dysfunction. **Hepatic failure** In patients aged > 6 years with beta-thalassemia, 4-6% had evidence of liver failure or cirrhosis. SCD patients can develop sickle cell crises and sequestration events affecting the liver causing massive hepatic enlargement with hepatic failure occurring in up to 10% of patients. Cirrhosis has been reported in 16 to 29% of SCD patients.
Risk factors and risk groups	**Increased liver transaminases** None identified **Hepatic failure** Patients with pre-existing hepatic impairment.
Risk minimization measures	**Increased liver transaminases / Hepatic failure** **Routine risk minimization measures** SmPC Section: 4.2 Posology and method of administration, 4.4 Special warnings and precautions for use. Relevant terms are included as ADR Section 4.8 Undesirable effects. **Additional risk minimization measures** None

Important identified risk: Gastrointestinal hemorrhage and ulcers; esophagitis	
Evidence for linking the risk to the medicine	No information was found regarding the incidence of this event in the unexposed population.
Risk factors and risk groups	Patients who are taking Oleptiss in combination with drugs that have known ulcerogenic potential, such as NSAIDs, corticosteroids or oral bisphosphonates, and in patients receiving

	anticoagulants.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.4 Special warnings and precautions for use, and 4.5 Interaction with other medicinal products and other forms of interaction. Relevant terms are included as ADRs in SmPC Section 4.8 Undesirable effects. **Additional risk minimization measures** None

Important identified risk: Hearing loss	
Evidence for linking the risk to the medicine	Hearing loss not attributed to chelation therapy has been reported in 28% of patients with beta-thalassemia. A study of 75 adults with SCD demonstrated that the prevalence of hearing loss was 41% and was higher than that of the general population.
Risk factors and risk groups	As with other iron chelator treatment, the risk of toxicity may be increased when inappropriately high doses are given in patients with a low iron burden or with serum ferritin levels that are only slightly elevated.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.4 Special warnings and precautions for use. Relevant terms are included as ADRs in Section 4.8 Undesirable effects. **Additional risk minimization measures** None

Important identified risk: Lens opacities, retinal changes and opticneuritis	
Evidence for linking the risk to the medicine	The background incidence of eye abnormalities in patients with beta-thalassemia is poorly documented. However, several reports document patients with lenticular opacities who have never received chelation therapy though the overall incidence was not provided. Cataracts have not been reported in patients with SCD. In the predominantly elderly patients with MDS, senile cataracts are a relatively frequent event.

Risk factors and risk groups	As with other iron chelator treatments, the risk of toxicity may be increased when inappropriately high doses are given in patients with a low iron burden or with serum ferritin levels that are only slightly elevated.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.4 Special warnings and precautions for use, 5.3 Preclinical safety data. Relevant terms are included as ADRs in Section 4.8 Undesirable effects. **Additional risk minimization measures** None

Important potential risk: Compliance with posology and biological monitoring	
Evidence for linking the risk to the medicine	Not applicable
Risk factors and risk groups	Patients who are non-compliant with posology and biological monitoring requirements in the SmPC.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.2 Posology and method of administration and 4.4 Special warnings and precautions for use. **Additional risk minimization measures** Educational materials for physicians (which also includes a prescriber checklist) and patients regardless of indication.

Important potential risk: Medication errors due to switching between Exjade FCT/granules and generic versions of Oleptiss DT	
Evidence for linking the risk to the medicine	Not applicable
Risk factors and risk groups	Patients may be at risk of medication errors during switch between Exjade FCT/granules and generic versions of Oleptiss DT available on the market by different MAHs and as appropriate depending on the coexistence of these formulations at a national level.
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.2 Posology and method of administration.

	Additional risk minimization measures Educational materials for physicians (which also includes a prescriber checklist) and patients clarifying the dose adjustment requirements in case of switch between Exjade FCT/granules and generic versions of Oleptiss DT.

Missing information: Long term safety in pediatric NTDT patients aged10 to 17 years	
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.2 Posology and method of administration, 4.4 Specialwarnings and precautions for use **Additional risk minimization measures** None
Additional pharmacovigilance activities	**Additional pharmacovigilance activities:** Study CICL670E2422: An observational, multi-center study to evaluate the safety of Oleptiss in the treatment of pediatric patients with non-transfusion-dependent iron overload.

Missing information: Use in children with renal function impairment	
Risk minimization measures	**Routine risk minimization measures** SmPC Section 4.2 and 5.2 and Patient Leaflet **Additional risk minimization measures** None
Additional pharmacovigilance activities	**Additional pharmacovigilance activities:** Study CICL670E2422: An observational, multi-center study to evaluate the safety of Oleptiss in the treatment of pediatric patients with non-transfusion-dependent iron overload.

II.C Post-authorization development plan

II.C.1 Studies which are conditions of the marketing authorization.

Study short name	Purpose of the study:	Milestone
CICL670E2422 (Observational study)	An observational, multicenter study to evaluate the safety of Oleptiss DTand FCT in pediatric NTDT patients aged 10 to 17-years old.	Protocol submission: Nov-2013 (Actual) Final CSR: Jul-2025 (Planned)

II.C.2 Other studies in post-authorization development plan

Not applicable.